>Marché des médicaments injectables lyophilisés en Asie-Pacifique, par emballage (flacons, seringues à double chambre, cartouches à double chambre et autres), classe de médicaments (anti-infectieux, antinéoplasiques, diurétiques, inhibiteurs de la pompe à protons, anesthésiques, anticoagulants, AINS, corticostéroïdes et autres), forme (poudre et liquide), indication (oncologie, maladies auto-immunes, troubles hormonaux, maladies respiratoires, troubles gastro-intestinaux, troubles dermatologiques, maladies ophtalmiques et autres), voie d'administration (intraveineuse/perfusion, intramusculaire et autres), utilisateur final (hôpital, cliniques, soins de santé à domicile et autres), canal de distribution (appel d'offres direct, vente au détail et autres), pays (Japon, Chine, Australie, Inde, Corée du Sud, Singapour, Indonésie, Thaïlande, Malaisie, Philippines, Vietnam, reste de l'Asie-Pacifique) Tendances de l'industrie et prévisions jusqu'en 2028.
Analyse et perspectives du marché : Marché des médicaments injectables lyophilisés en Asie-Pacifique
Le marché des médicaments injectables lyophilisés devrait connaître une croissance du marché au cours de la période de prévision de 2021 à 2028. Data Bridge Market Research analyse que le marché croît avec un TCAC de 7,7 % et devrait atteindre 1 351,81 millions USD au cours de la période de prévision de 2021 à 2028. Un grand nombre d'acteurs du marché sont impliqués dans l'offre de produits de médicaments injectables lyophilisés avec des innovations qui ouvrent la voie à la croissance du marché des médicaments injectables lyophilisés.
La lyophilisation est une méthode de lyophilisation permettant d'éliminer l'eau d'un produit fini. Les produits issus de la lyophilisation sont congelés sous vide poussé. Dans les industries biotechnologiques et pharmaceutiques, le processus de lyophilisation est utilisé pour créer des produits de haute qualité avec une durée de conservation plus longue.
L'augmentation des maladies chroniques, l'augmentation de la population gériatrique et globale souffrant de troubles cardiaques et neurologiques, l'expansion du pipeline de médicaments injectables lyophilisés, la réduction du risque d'administration de médicaments injectables lyophilisés avec des seringues de diluant préremplies et les progrès technologiques dus à l'augmentation de la R&D stimulent le marché des médicaments injectables lyophilisés en Asie-Pacifique.
De plus, la lyophilisation permet de transporter et de stocker ces substances en toute sécurité jusqu'à leur utilisation. Les médicaments injectables doivent désormais être lyophilisés en raison de problèmes de sécurité accrus. Après une longue période de stockage, les médicaments injectables lyophilisés se sont avérés plus sûrs et plus pratiques à administrer que d'autres produits séchés.
Le rapport sur le marché des médicaments injectables lyophilisés fournit des détails sur la part de marché, les nouveaux développements et l'analyse du pipeline de produits, l'impact des acteurs du marché national et local, analyse les opportunités en termes de poches de revenus émergentes, de changements dans la réglementation du marché, d'approbations de produits, de décisions stratégiques, de lancements de produits, d'expansions géographiques et d'innovations technologiques sur le marché. Pour comprendre l'analyse et le scénario du marché, contactez-nous pour un briefing d'analyste, notre équipe vous aidera à créer une solution d'impact sur les revenus pour atteindre votre objectif souhaité.
Portée et taille du marché des médicaments injectables lyophilisés en Asie-Pacifique
Le marché des médicaments injectables lyophilisés est divisé en sept segments notables qui sont basés sur l'emballage, la classe de médicament, la forme, l'indication, la voie d'administration, l'utilisateur final et le canal de distribution. La croissance entre les segments vous aide à analyser les niches de croissance et les stratégies pour aborder le marché et déterminer vos principaux domaines d'application et la différence entre vos marchés cibles.
- Sur la base de l'emballage, le marché des médicaments injectables lyophilisés est segmenté en flacons, seringues à double chambre, cartouches à double chambre et autres. En 2021, le segment des flacons devrait dominer le marché des médicaments injectables lyophilisés, car la plupart des médicaments injectables lyophilisés sont conditionnés dans des flacons, ce qui lui confère une influence et une croissance sur le marché.
- Sur la base de la classe de médicaments, le marché des médicaments injectables lyophilisés est segmenté en anti-infectieux, antinéoplasiques, diurétiques , inhibiteurs de la pompe à protons, anesthésiques, anticoagulants, AINS, corticostéroïdes et autres. En 2021, le segment des anti-infectieux devrait dominer le marché des médicaments injectables lyophilisés en raison de la forte prévalence des maladies chroniques dans la région asiatique, qui favorise le besoin d'antibiotiques et de médicaments antiviraux.
- Sur la base de la forme, le marché des médicaments injectables lyophilisés est segmenté en poudre et en liquide. En 2021, le segment de la poudre devrait dominer le marché des médicaments injectables lyophilisés car il est très utilisé dans le stockage et le transport dans la région Asie-Pacifique.
- Sur la base des indications, le marché des médicaments injectables lyophilisés est segmenté en oncologie , maladies auto-immunes, troubles hormonaux, maladies respiratoires, troubles gastro-intestinaux, troubles dermatologiques, maladies ophtalmiques et autres. En 2021, le segment oncologique devrait dominer le marché des médicaments injectables lyophilisés, car les médicaments injectables lyophilisés sont très utilisés en oncologie dans la région asiatique.
- En fonction de la voie d'administration, le marché des médicaments injectables lyophilisés est segmenté en intraveineux/perfusion, intramusculaire et autres. En 2021, le segment intraveineux/perfusion devrait dominer le marché des médicaments injectables lyophilisés en raison de la biodisponibilité à 100 % du médicament via cette voie d'administration.
- Sur la base de l'utilisateur final, le marché des médicaments injectables lyophilisés est segmenté en hôpitaux, cliniques, soins à domicile et autres. En 2021, le segment hospitalier devrait dominer le marché des médicaments injectables lyophilisés en raison de la présence de professionnels qualifiés dans la région asiatique.
- Sur la base du canal de distribution, le marché des médicaments injectables lyophilisés est segmenté en appels d'offres directs, ventes au détail et autres. En 2021, le segment des appels d'offres directs devrait dominer le marché des médicaments injectables lyophilisés car la demande d'appels d'offres directs est élevée dans la région Asie-Pacifique.
Analyse du marché des médicaments injectables lyophilisés au niveau des pays
Le marché des médicaments injectables lyophilisés est analysé et des informations sur la taille du marché sont fournies par pays, emballage, classe de médicament, forme, indication, voie d'administration, utilisateur final et canal de distribution comme référencé ci-dessus.
Les pays couverts par le marché des médicaments injectables lyophilisés en Asie-Pacifique sont le Japon, la Chine, l'Australie, l'Inde, la Corée du Sud, Singapour, l'Indonésie, la Thaïlande, la Malaisie, les Philippines, le Vietnam et le reste de l'Asie-Pacifique.
La Chine devrait dominer le marché en raison de l’augmentation des maladies chroniques et de l’augmentation de la population gériatrique atteinte de maladies chroniques.
La section par pays du rapport fournit également des facteurs d'impact sur les marchés individuels et des changements de réglementation sur le marché national qui ont un impact sur les tendances actuelles et futures du marché. Des points de données tels que les nouvelles ventes, les ventes de remplacement, la démographie des pays, les actes réglementaires et les tarifs d'importation et d'exportation sont quelques-uns des principaux indicateurs utilisés pour prévoir le scénario de marché pour les différents pays. En outre, la présence et la disponibilité des marques d'Asie-Pacifique et les défis auxquels elles sont confrontées en raison de la concurrence importante ou rare des marques locales et nationales, l'impact des canaux de vente sont pris en compte lors de l'analyse prévisionnelle des données nationales.
Les lancements de nouveaux produits par les fabricants créent de nouvelles opportunités pour les acteurs du marché des médicaments injectables lyophilisés
Le marché des médicaments injectables lyophilisés vous fournit également une analyse de marché détaillée pour chaque pays, la croissance de l'industrie esthétique avec les ventes du marché des médicaments injectables lyophilisés, l'impact des progrès sur le marché des médicaments injectables lyophilisés et les changements dans les scénarios réglementaires avec leur soutien au marché des médicaments injectables lyophilisés. Les données sont disponibles pour la période historique de 2010 à 2019.
Analyse du paysage concurrentiel et des parts de marché des médicaments injectables lyophilisés
Le paysage concurrentiel du marché des médicaments injectables lyophilisés fournit des détails par concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, les sites et installations de production, les forces et les faiblesses de l'entreprise, le lancement de produits, les pipelines d'essais de produits, les approbations de produits, les brevets, la largeur et l'étendue du produit, la domination des applications, la courbe de survie technologique. Les points de données ci-dessus fournis ne concernent que l'orientation de l'entreprise liée au marché des médicaments injectables lyophilisés.
Les principales entreprises fournissant des médicaments injectables lyophilisés sur le marché des médicaments injectables lyophilisés en Asie-Pacifique sont Affy Pharma Pvt Ltd., Genex Pharma, AuroMedics Pharma LLC Pharma LLC (une filiale d'Aurobindo Pharma), Astellas Pharma US, Inc. (une filiale d'Astellas Pharma Inc.), Aristopharma Ltd., Pfizer Inc., Sanofi, Celon Laboratories Pvt. Ltd. et Baxter, entre autres. Les analystes de DBMR comprennent les atouts de la concurrence et fournissent une analyse concurrentielle pour chaque concurrent séparément.
De nombreux contrats et accords sont également initiés par les entreprises du monde entier qui accélèrent également le marché des médicaments injectables lyophilisés.
- En novembre 2019, Pfizer, Inc. a annoncé que sa division, nommée Upjohn, a fusionné avec Mylan NV et a formé une nouvelle société nommée Viatris Inc. Cette combinaison de la division commerciale de la société avec Mylan NV a augmenté son portefeuille de produits, entraînant une demande accrue pour son produit sur le marché.
La collaboration, les coentreprises et d’autres stratégies des acteurs du marché améliorent le marché de l’entreprise sur le marché des médicaments injectables lyophilisés, ce qui offre également l’avantage à l’organisation d’améliorer son offre pour le marché des médicaments injectables lyophilisés.
SKU-
Accédez en ligne au rapport sur le premier cloud mondial de veille économique
- Tableau de bord d'analyse de données interactif
- Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
- Accès d'analyste de recherche pour la personnalisation et les requêtes
- Analyse de la concurrence avec tableau de bord interactif
- Dernières actualités, mises à jour et analyse des tendances
- Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Table des matières
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PACKAGING LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 MARKET END USER COVERAGE GRID
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: REGULATORY FRAMEWORK
5 EPIDEMIOLOGY
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 RISE IN CHRONIC HEALTH CONDITIONS
6.1.2 SAFE TRANSIT AND STORAGE OF THESE SUBSTANCES UNTIL THEIR END-USE
6.1.3 INCREASE IN GERIATRIC POPULATION WITH CHRONIC DISEASES
6.1.4 EXPANSION OF PIPELINE OF LYOPHILIZED INJECTABLE DRUGS
6.1.5 TECHNOLOGICAL ADVANCEMENTS
6.2 RESTRAINTS
6.2.1 RISK OF NEEDLESTICK INJURIES
6.2.2 INCREASE IN NUMBER OF PRODUCT RECALLS FOR LYOPHILIZED DRUGS AND PACKAGING TYPE
6.3 OPPORTUNITIES
6.3.1 RISE IN REGULATORY APPROVALS FOR LYOPHILIZED DRUGS
6.3.2 STRATEGIC INITIATIVES OF KEY MARKET PLAYERS
6.3.3 QUALITY CONCERNS
6.4 CHALLENGES
6.4.1 CHALLENGES ASSOCIATED WITH MANUFACTURING LYOPHILIZED VIALS FOR PARENTERAL PRODUCTS
6.4.2 TIME-CONSUMING PROCESS AND HIGH COST
7 IMPACT OF COVID-19 ON THE ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET
7.1 IMPACT ON PRICE
7.2 IMPACT IN DEMAND
7.3 IMPACT ON SUPPLY
7.4 STRATEGIC INITIATIVE
7.5 CONCLUSION
8 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING
8.1 OVERVIEW
8.2 VIALS
8.3 DUAL-CHAMBER SYRINGES
8.4 DUAL-CHAMBER CARTRIDGES
8.5 OTHERS
9 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS
9.1 OVERVIEW
9.2 ANTI-INFECTIVE’S
9.2.1 ANTIBIOTICS
9.2.1.1 Azithromycin
9.2.1.2 Doxycycline
9.2.1.3 Vancomycin
9.2.1.4 Polymyxin B
9.2.1.5 Piperacillin
9.2.1.6 Tazobactam
9.2.1.7 Others
9.2.2 ANTIFUNGAL
9.2.2.1 Mycamine
9.2.2.2 Caspofungin Acetate
9.2.2.3 Isavuconazonium Sulfate
9.2.2.4 Amphotericin
9.2.2.5 Others
9.2.3 ANTIVIRAL
9.2.3.1 Acyclovir
9.2.3.2 Ganciclovir
9.2.3.3 Remdesivir
9.2.3.4 Others
9.2.4 OTHERS
9.3 ANTINEOPLASTIC
9.3.1 METHOTREXATE
9.3.2 GEMCITABINE
9.3.3 CYTARABINE
9.3.4 FLUDARABINE
9.3.5 DOXORUBICIN
9.3.6 OXALIPLATIN
9.3.7 ZOLEDRONIC ACID
9.3.8 OTHERS
9.4 DIURETICS
9.4.1 CHLOROTHIAZIDE
9.4.2 ETHACRYNIC ACID
9.4.3 ACETAZOLAMIDE
9.4.4 OTHERS
9.5 PROTON PUMP INHIBITOR
9.5.1 ESOMEPRAZOLE SODIUM
9.5.2 PANTOPRAZOLE SODIUM
9.5.3 OMEPRAZOLE
9.5.4 OTHERS
9.6 ANESTHETIC
9.6.1 VECURONIUM BROMIDE
9.6.2 SODIUM THIOPENTAL
9.6.3 LIDOCAINE
9.6.4 OTHERS
9.7 ANTICOAGULANT
9.7.1 COUMADIN
9.7.2 UROKINASE
9.7.3 ANTITHROMBIN (RECOMBINANT)
9.7.4 APIXABAN
9.7.5 RIVAROXABAN
9.7.6 OTHERS
9.8 NSAID’S
9.8.1 INDOMETHACIN
9.8.2 IBUPROFEN
9.8.3 DICLOFENAC
9.8.4 KETOROLAC
9.8.5 OTHERS
9.9 CORTICOSTEROIDS
9.9.1 HYDROCORTISONE
9.9.2 METHYLPREDNISOLONE
9.9.3 OTHERS
9.1 OTHERS
10 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM
10.1 OVERVIEW
10.2 POWDER
10.3 LIQUID
11 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION
11.1 OVERVIEW
11.2 ONCOLOGY
11.3 AUTOIMMUNE DISEASES
11.4 HORMONAL DISORDERS
11.5 RESPIRATORY DISEASES
11.6 GASTROINTESTINAL DISORDERS
11.7 DERMATOLOGICAL DISORDERS
11.8 OPHTHALMIC DISEASES
11.9 OTHERS
12 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION
12.1 OVERVIEW
12.2 INTRAVENOUS/INFUSION
12.3 INTRAMUSCULAR
12.4 OTHERS
13 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER
13.1 OVERVIEW
13.2 HOSPITAL
13.3 CLINICS
13.4 HOME HEALTHCARE
13.5 OTHERS
14 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL
14.1 OVERVIEW
14.2 DIRECT TENDERS
14.3 RETAIL SALES
14.4 OTHERS
15 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION
15.1 ASIA-PACIFIC
15.1.1 JAPAN
15.1.2 CHINA
15.1.3 SOUTH KOREA
15.1.4 INDIA
15.1.5 AUSTRALIA
15.1.6 SINGAPORE
15.1.7 THAILAND
15.1.8 MALAYSIA
15.1.9 INDONESIA
15.1.10 PHILIPPINES
15.1.11 VIETNAM
15.1.12 REST OF ASIA-PACIFIC
16 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: COMPANY LANDSCAPE
16.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
17 SWOT ANALYSIS
18 COMPANY PROFILE
18.1 PFIZER INC.
18.1.1 COMPANY SNAPSHOT
18.1.2 REVENUE ANALYSIS
18.1.3 COMPANY SHARE ANALYSIS
18.1.4 PRODUCT PORTFOLIO
18.1.5 RECENT DEVELOPMENT
18.2 FRESENIUS KABI USA (A SUBSIDIARY OF FRESENIUS KABI AG)
18.2.1 COMPANY SNAPSHOT
18.2.2 REVENUE ANALYSIS
18.2.3 COMPANY SHARE ANALYSIS
18.2.4 PRODUCT PORTFOLIO
18.2.5 RECENT DEVELOPMENTS
18.3 CIPLA INC.
18.3.1 COMPANY SNAPSHOT
18.3.2 REVENUE ANALYSIS
18.3.3 COMPANY SHARE ANALYSIS
18.3.4 PRODUCT PORTFOLIO
18.3.5 RECENT DEVELOPMENT
18.4 NOVARTIS AG
18.4.1 COMPANY SNAPSHOT
18.4.2 REVENUE ANALYSIS
18.4.3 COMPANY SHARE ANALYSIS
18.4.4 PRODUCT PORTFOLIO
18.4.5 RECENT DEVELOPMENT
18.5 MERCK SHARP & DOHME CORP., A SUBSIDIARY OF MERCK & CO., INC.
18.5.1 COMPANY SNAPSHOT
18.5.2 REVENUE ANALYSIS
18.5.3 PRODUCT PORTFOLIO
18.5.4 RECENT DEVELOPMENT
18.6 BAXTER
18.6.1 COMPANY SNAPSHOT
18.6.2 REVENUE ANALYSIS
18.6.3 PRODUCT PORTFOLIO
18.6.4 RECENT DEVELOPMENTS
18.7 ZYDUS CADILA
18.7.1 COMPANY SNAPSHOT
18.7.2 REVENUE ANALYSIS
18.7.3 PRODUCT PORTFOLIO
18.7.4 RECENT DEVELOPMENT
18.8 AFFY PHARMA PVT LTD.
18.8.1 COMPANY SNAPSHOT
18.8.2 PRODUCT PORTFOLIO
18.8.3 RECENT DEVELOPMENT
18.9 AMNEAL PHARMACEUTICALS LLC
18.9.1 COMPANY SNAPSHOT
18.9.2 REVENUE ANALYSIS
18.9.3 PRODUCT PORTFOLIO
18.9.4 RECENT DEVELOPMENTS
18.1 ARISTOPHARMA LTD.
18.10.1 COMPANY SNAPSHOT
18.10.2 PRODUCT PORTFOLIO
18.10.3 RECENT DEVELOPMENT
18.11 ASTELLAS PHARMA US, INC. (A SUBSIDIARY OF ASTELLAS PHARMA INC.)
18.11.1 COMPANY SNAPSHOT
18.11.2 REVENUE ANALYSIS
18.11.3 PRODUCT PORTFOLIO
18.11.4 RECENT DEVELOPMENTS
18.12 AUROMEDICS PHARMA LLC (A SUBSIDIARY OF AUROBINDO PHARMA)
18.12.1 COMPANY SNAPSHOT
18.12.2 REVENUE ANALYSIS
18.12.3 PRODUCT PORTFOLIO
18.12.4 RECENT DEVELOPMENTS
18.13 CELON LABORATORIES PVT.LTD.
18.13.1 COMPANY SNAPSHOT
18.13.2 PRODUCT PORTFOLIO
18.13.3 RECENT DEVELOPMENT
18.14 CIRONDRUGS
18.14.1 COMPANY SNAPSHOT
18.14.2 PRODUCT PORTFOLIO
18.14.3 RECENT DEVELOPMENT
18.15 GENEX PHARMA
18.15.1 COMPANY SNAPSHOT
18.15.2 PRODUCT PORTFOLIO
18.15.3 RECENT DEVELOPMENT
18.16 GILEAD SCIENCES, INC.
18.16.1 COMPANY SNAPSHOT
18.16.2 REVENUE ANALYSIS
18.16.3 PRODUCT PORTFOLIO
18.16.4 RECENT DEVELOPMENTS
18.17 JUBILANT GENERICS LIMITED – A JUBILANT PHARMA COMPANY
18.17.1 COMPANY SNAPSHOT
18.17.2 REVENUE ANALYSIS
18.17.3 PRODUCT PORTFOLIO
18.17.4 RECENT DEVELOPMENTS
18.18 OTSUKA AMERICA PHARMACEUTICAL, INC
18.18.1 COMPANY SNAPSHOT
18.18.2 PRODUCT PORTFOLIO
18.18.3 RECENT DEVELOPMENTS
18.19 SANOFI
18.19.1 COMPANY SNAPSHOT
18.19.2 REVENUE ANALYSIS
18.19.3 PRODUCT PORTFOLIO
18.19.4 RECENT DEVELOPMENT
18.2 VIATRIS INC.
18.20.1 COMPANY SNAPSHOT
18.20.2 REVENUE ANALYSIS
18.20.3 PRODUCT PORTFOLIO
18.20.4 RECENT DEVELOPMENT
19 QUESTIONNAIRE
20 RELATED REPORTS
Liste des tableaux
TABLE 1 PIPELINE LYOPHILIZED INJECTABLE DRUGS
TABLE 2 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)
TABLE 3 ASIA-PACIFIC VIALS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 4 ASIA-PACIFIC DUAL-CHAMBER SYRINGES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 5 ASIA-PACIFIC DUAL-CHAMBER CARTRIDGES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 6 ASIA-PACIFIC OTHERS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 7 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 8 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)
TABLE 9 ASIA-PACIFIC ANTI-INFECTIVE’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 10 ASIA-PACIFIC ANTI-INFECTIVE’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 11 ASIA-PACIFIC ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 12 ASIA-PACIFIC ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 13 ASIA-PACIFIC ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 14 ASIA-PACIFIC ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 15 ASIA-PACIFIC ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 16 ASIA-PACIFIC DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 17 ASIA-PACIFIC DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 18 ASIA-PACIFIC PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 19 ASIA-PACIFIC PROTON PUMP INHIBITORS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 20 ASIA-PACIFIC ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 21 ASIA-PACIFIC ANESTHETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 22 ASIA-PACIFIC ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 23 ASIA-PACIFIC ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 24 ASIA-PACIFIC NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 25 ASIA-PACIFIC NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 26 ASIA-PACIFIC CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 27 ASIA-PACIFIC CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 28 ASIA-PACIFIC OTHERS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 29 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)
TABLE 30 ASIA-PACIFIC POWDER IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 31 ASIA-PACIFIC LIQUID IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 32 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 33 ASIA-PACIFIC ONCOLOGY IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 34 ASIA-PACIFIC AUTOIMMUNE DISEASES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 35 ASIA-PACIFIC HORMONAL DISORDERS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 36 ASIA-PACIFIC RESPIRATORY DISEASES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 37 ASIA-PACIFIC GASTROINTESTINAL DISORDERS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 38 ASIA-PACIFIC DERMATOLOGICAL DISORDERS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 39 ASIA-PACIFIC OPHTHALMIC DISEASES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 40 ASIA-PACIFIC OTHERS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 41 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 42 ASIA-PACIFIC INTRAVENOUS/INFUSION IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 43 ASIA-PACIFIC INTRAMUSCULAR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 44 ASIA-PACIFIC OTHERS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 45 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 46 ASIA-PACIFIC HOSPITAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 47 ASIA-PACIFIC CLINICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 48 ASIA-PACIFIC HOME HEALTHCARE IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 49 ASIA-PACIFIC OTHERS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 50 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 51 ASIA-PACIFIC DIRECT TENDER IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 52 ASIA-PACIFIC RETAIL SALES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 53 ASIA-PACIFIC OTHERS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 54 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 55 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)
TABLE 56 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 57 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)
TABLE 58 ASIA-PACIFIC ANTI-INFECTIVES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 59 ASIA-PACIFIC ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 60 ASIA-PACIFIC ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 61 ASIA-PACIFIC ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 62 ASIA-PACIFIC ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 63 ASIA-PACIFIC DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 64 ASIA-PACIFIC PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 65 ASIA-PACIFIC ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 66 ASIA-PACIFIC ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 67 ASIA-PACIFIC NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 68 ASIA-PACIFIC CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 69 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)
TABLE 70 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 71 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 72 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 73 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 74 JAPAN LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)
TABLE 75 JAPAN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 76 JAPAN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)
TABLE 77 JAPAN ANTI-INFECTIVES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 78 JAPAN ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 79 JAPAN ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 80 JAPAN ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 81 JAPAN ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 82 JAPAN DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 83 JAPAN PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 84 JAPAN ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 85 JAPAN ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 86 JAPAN NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 87 JAPAN CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 88 JAPAN LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)
TABLE 89 JAPAN LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 90 JAPAN LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 91 JAPAN LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 92 JAPAN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 93 CHINA LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)
TABLE 94 CHINA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 95 CHINA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)
TABLE 96 CHINA ANTI-INFECTIVES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 97 CHINA ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 98 CHINA ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 99 CHINA ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 100 CHINA ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 101 CHINA DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 102 CHINA PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 103 CHINA ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 104 CHINA ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 105 CHINA NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 106 CHINA CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 107 CHINA LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)
TABLE 108 CHINA LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 109 CHINA LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 110 CHINA LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 111 CHINA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 112 SOUTH KOREA LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)
TABLE 113 SOUTH KOREA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 114 SOUTH KOREA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)
TABLE 115 SOUTH KOREA ANTI-INFECTIVES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 116 SOUTH KOREA ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 117 SOUTH KOREA ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 118 SOUTH KOREA ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 119 SOUTH KOREA ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 120 SOUTH KOREA DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 121 SOUTH KOREA PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 122 SOUTH KOREA ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 123 SOUTH KOREA ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 124 SOUTH KOREA NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 125 SOUTH KOREA CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 126 SOUTH KOREA LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)
TABLE 127 SOUTH KOREA LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 128 SOUTH KOREA LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 129 SOUTH KOREA LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 130 SOUTH KOREA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 131 INDIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)
TABLE 132 INDIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 133 INDIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)
TABLE 134 INDIA ANTI-INFECTIVES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 135 INDIA ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 136 INDIA ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 137 INDIA ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 138 INDIA ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 139 INDIA DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 140 INDIA PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 141 INDIA ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 142 INDIA ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 143 INDIA NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 144 INDIA CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 145 INDIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)
TABLE 146 INDIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 147 INDIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 148 INDIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 149 INDIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 150 AUSTRALIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)
TABLE 151 AUSTRALIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 152 AUSTRALIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)
TABLE 153 AUSTRALIA ANTI-INFECTIVES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 154 AUSTRALIA ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 155 AUSTRALIA ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 156 AUSTRALIA ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 157 AUSTRALIA ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 158 AUSTRALIA DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 159 AUSTRALIA PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 160 AUSTRALIA ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 161 AUSTRALIA ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 162 AUSTRALIA NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 163 AUSTRALIA CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 164 AUSTRALIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)
TABLE 165 AUSTRALIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 166 AUSTRALIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 167 AUSTRALIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 168 AUSTRALIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 169 SINGAPORE LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)
TABLE 170 SINGAPORE LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 171 SINGAPORE LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)
TABLE 172 SINGAPORE ANTI-INFECTIVES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 173 SINGAPORE ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 174 SINGAPORE ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 175 SINGAPORE ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 176 SINGAPORE ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 177 SINGAPORE DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 178 SINGAPORE PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 179 SINGAPORE ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 180 SINGAPORE ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 181 SINGAPORE NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 182 SINGAPORE CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 183 SINGAPORE LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)
TABLE 184 SINGAPORE LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 185 SINGAPORE LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 186 SINGAPORE LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 187 SINGAPORE LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 188 THAILAND LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)
TABLE 189 THAILAND LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 190 THAILAND LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)
TABLE 191 THAILAND ANTI-INFECTIVES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 192 THAILAND ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 193 THAILAND ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 194 THAILAND ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 195 THAILAND ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 196 THAILAND DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 197 THAILAND PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 198 THAILAND ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 199 THAILAND ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 200 THAILAND NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 201 THAILAND CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 202 THAILAND LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)
TABLE 203 THAILAND LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 204 THAILAND LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 205 THAILAND LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 206 THAILAND LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 207 MALAYSIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)
TABLE 208 MALAYSIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 209 MALAYSIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)
TABLE 210 MALAYSIA ANTI-INFECTIVES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 211 MALAYSIA ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 212 MALAYSIA ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 213 MALAYSIA ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 214 MALAYSIA ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 215 MALAYSIA DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 216 MALAYSIA PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 217 MALAYSIA ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 218 MALAYSIA ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 219 MALAYSIA NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 220 MALAYSIA CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 221 MALAYSIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)
TABLE 222 MALAYSIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 223 MALAYSIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 224 MALAYSIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 225 MALAYSIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 226 INDONESIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)
TABLE 227 INDONESIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 228 INDONESIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)
TABLE 229 INDONESIA ANTI-INFECTIVES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 230 INDONESIA ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 231 INDONESIA ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 232 INDONESIA ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 233 INDONESIA ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 234 INDONESIA DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 235 INDONESIA PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 236 INDONESIA ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 237 INDONESIA ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 238 INDONESIA NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 239 INDONESIA CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 240 INDONESIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)
TABLE 241 INDONESIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 242 INDONESIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 243 INDONESIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 244 INDONESIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 245 PHILIPPINES LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)
TABLE 246 PHILIPPINES LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 247 PHILIPPINES LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)
TABLE 248 PHILIPPINES ANTI-INFECTIVES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 249 PHILIPPINES ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 250 PHILIPPINES ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 251 PHILIPPINES ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 252 PHILIPPINES ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 253 PHILIPPINES DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 254 PHILIPPINES PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 255 PHILIPPINES ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 256 PHILIPPINES ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 257 PHILIPPINES NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 258 PHILIPPINES CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 259 PHILIPPINES LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)
TABLE 260 PHILIPPINES LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 261 PHILIPPINES LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 262 PHILIPPINES LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 263 PHILIPPINES LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 264 VIETNAM LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)
TABLE 265 VIETNAM LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 266 VIETNAM LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)
TABLE 267 VIETNAM ANTI-INFECTIVES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 268 VIETNAM ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 269 VIETNAM ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 270 VIETNAM ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 271 VIETNAM ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 272 VIETNAM DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 273 VIETNAM PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 274 VIETNAM ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 275 VIETNAM ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 276 VIETNAM NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 277 VIETNAM CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 278 VIETNAM LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)
TABLE 279 VIETNAM LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 280 VIETNAM LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 281 VIETNAM LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 282 VIETNAM LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 283 REST OF ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)
Liste des figures
FIGURE 1 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: SEGMENTATION
FIGURE 2 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: DATA TRIANGULATION
FIGURE 3 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: DROC ANALYSIS
FIGURE 4 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: ASIA-PACIFIC VS. REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: MULTIVARIATE MODELLING
FIGURE 7 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: DBMR MARKET POSITION GRID
FIGURE 9 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: MARKET END USER COVERAGE GRID
FIGURE 11 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: SEGMENTATION
FIGURE 12 RISE IN CHRONIC HEALTH CONDITIONS IS EXPECTED TO DRIVE THE ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 13 VIALS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET IN 2021 & 2028
FIGURE 14 ASIA-PACIFIC IS THE FASTEST GROWING MARKET FOR THE LYOPHILIZED INJECTABLE DRUGS MANUFACTURERS IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET
FIGURE 16 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY PACKAGING, 2020
FIGURE 17 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY PACKAGING, 2021-2028 (USD MILLION)
FIGURE 18 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY PACKAGING, CAGR (2021-2028)
FIGURE 19 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY PACKAGING, LIFELINE CURVE
FIGURE 20 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY DRUG CLASS, 2020
FIGURE 21 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY DRUG CLASS, 2021-2028 (USD MILLION)
FIGURE 22 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY DRUG CLASS, CAGR (2021-2028)
FIGURE 23 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY DRUG CLASS, LIFELINE CURVE
FIGURE 24 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY FORM, 2020
FIGURE 25 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY FORM, 2021-2028 (USD MILLION)
FIGURE 26 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY FORM, CAGR (2021-2028)
FIGURE 27 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY FORM, LIFELINE CURVE
FIGURE 28 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY INDICATION, 2020
FIGURE 29 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY INDICATION, 2021-2028 (USD MILLION)
FIGURE 30 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY INDICATION, CAGR (2021-2028)
FIGURE 31 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY INDICATION, LIFELINE CURVE
FIGURE 32 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2020
FIGURE 33 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
FIGURE 34 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2021-2028)
FIGURE 35 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 36 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY END USER, 2020
FIGURE 37 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY END USER, 2021-2028 (USD MILLION)
FIGURE 38 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY END USER, CAGR (2021-2028)
FIGURE 39 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY END USER, LIFELINE CURVE
FIGURE 40 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 41 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
FIGURE 42 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)
FIGURE 43 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 44 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: SNAPSHOT (2020)
FIGURE 45 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY COUNTRY (2020)
FIGURE 46 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY COUNTRY (2021 & 2028)
FIGURE 47 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY COUNTRY (2020 & 2028)
FIGURE 48 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY PACKAGING (2021-2028)
FIGURE 49 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: COMPANY SHARE 2020 (%)
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.
La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.
Personnalisation disponible
Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.
